The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review
Open accessAbstract
BACKGROUND: We identified anti-obesity medications withdrawn since 1950 because of adverse drug reactions after regulatory approval, and examined the evidence used to support such withdrawals, investigated the mechanisms of the adverse reactions, and explored the trends over time. METHODS: We conducted searches in PubMed, the World Health Organization database of drugs, the websites of drug regulatory authorities, and selected full texts, and we hand searched references in retrieved documents. We included anti-obesity medications that were withdrawn between 1950 and December 2015 and assessed the levels of evidence used for making withdrawal decisions using the Oxford Centre for Evidence-Based Medicine criteria. RESULTS: We identified 25 anti-obesity medications withdrawn between 1964 and 2009; 23 of these were centrally acting, via monoamine neurotransmitters. Case reports were cited as evidence for withdrawal in 80% of instances. Psychiatric disturbances, cardiotoxicity (mainly attributable to re-uptake inhibitors), and drug abuse or dependence (mainly attributable to neurotransmitter releasing agents) together accounted for 83% of withdrawals. Deaths were reportedly associated with seven products (28%). In almost half of the cases, the withdrawals occurred within 2 years of the first report of an adverse reaction. CONCLUSIONS: Most of the drugs that affect monoamine neurotransmitters licensed for the treatment of obesity over the past 65 years have been withdrawn because of adverse reactions. The reasons for withdrawal raise concerns about the wisdom of using pharmacological agents that target monoamine neurotransmitters in managing obesity. Greater transparency in the assessment of harms from anti-obesity medications is therefore warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“have demonstrated an average body weight loss of ≤10% after one year, but with serious safety concerns such as cardiotoxicity, neuropsychiatric disorders, and cancer (6).”
From Regional trends and disparities in newer GLP1 receptor agonist initiation among real‐world adult patients eligible for obesity treatment (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908 · cited 1×
“6 years) showed that weight reduction did not reduce the risk of adverse cardiovascular events in obese and overweight adults with type 2 diabetes [29].”
BackgroundValvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Foresight. Tackling obesities: future choices. Project report.
Butland, B. K., Jebb, S. A., Kopelman, P., McPherson, K., Thomas, S., Mardell, J., & Parry, V. G. (2007) · Cited by 832
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Onakpoya, I., Heneghan, C. J., & Aronson, J. K. (2016) · BMC Medicine · doi:10.1186/s12916-016-0553-2 · Cited by 617
Self-citationAnti-Obesity Drugs: A Review about Their Effects and Safety
Kang, J. G., & Park, C. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.13 · Cited by 605
Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 565
O'Neil, P. M., Smith, S. R., Weissman, N. J., Fidler, M. C., Sanchez, M., Zhang, J., Raether, B., Anderson, C. M., & Shanahan, W. R. (2012) · Obesity · doi:10.1038/oby.2012.66 · Cited by 525
Research works printed but not linked: 3
- OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. 2016. http://www.cebm.net/ocebm-levels-of-evidence/ .
- Price K. Case notes: phentermine. Bull Int Assoc Foren Toxicol. 1974;10(1):12.
- Anonymous. Italy suspends sibutramine licence. Pharm J. 2002;268(7190):385–91.
Cited by
Sorted by citations
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Ng, M., Dai, X., Cogen, R. M., Abdelmasseh, M., Abdollahi, A., Abdullahi, A., Aboagye, R. G., Abukhadijah, H. J., Adeyeoluwa, T. E., Afolabi, A. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01548-4 · Cited by 407
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Polypharmacology: The science of multi-targeting molecules
Kabir, A., & Muth, A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2021.106055 · Cited by 245
González, N., Moreno-Villegas, Z., González-Bris, A., Egido, J., & Lorenzo, Ó. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0528-4 · Cited by 211
“Thus, only five anti-obesity drugs have been approved by the FDA for long-term treatments [101], but their role in VAT, and overall EAT, is rather unknown.”
BackgroundThe Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity
Bliss, E., & Whiteside, E. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00900 · Cited by 196
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146
Shaik Mohamed Sayed, U. F., Moshawih, S., Goh, H. P., Kifli, N., Gupta, G., Singh, S. K., Chellappan, D. K., Dua, K., Hermansyah, A., Ser, H. L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182937 · Cited by 136
Wang, T., Han, J., Dai, H., Sun, J., Ren, J., Wang, W., Qiao, S., Liu, C., Sun, L., Liu, S., et al. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119862 · Cited by 139
Pan, H., Fu, C., Huang, L., Jiang, Y., Deng, X., Guo, J., & Su, Z. (2018) · Marine Drugs · doi:10.3390/md16060198 · Cited by 88
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
Burnett, S. D., Blanchette, A. D., Chiu, W. A., & Rusyn, I. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1894122 · Cited by 79
Onakpoya, I., Lee, J. J., Mahtani, K. R., Aronson, J. K., & Heneghan, C. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14210 · Cited by 76
Self-citationLi, R., Curtain, C. M., Bereznicki, L., & Zaidi, S. T. R. (2018) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-0700-2 · Cited by 73
Jin, L., Yang, R., Geng, L., & Xu, A. (2023) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032322-093904 · Cited by 71
Ekert, J. E., Deakyne, J., Pribul-Allen, P., Terry, R., Schofield, C., Jeong, C. G., Storey, J., Mohamet, L., Francis, J., Naidoo, A., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220923332 · Cited by 68
Yan, C., Zeng, T., Lee, K., Nobis, M., Loh, K., Gou, L., Xia, Z., Gao, Z., Bensellam, M., Hughes, W. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22925-3 · Cited by 61
Obesity: exploring its connection to brain function through genetic and genomic perspectives
Saeed, S., Bonnefond, A., & Froguel, P. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02737-9 · Cited by 57
Li, W., Zhuang, T., Wang, Z., Wang, X., Liu, L., Luo, Y., Wang, R., Li, L., Huang, W., Wang, Z., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154982 · Cited by 49
Human Organs‐on‐Chips: A Review of the State‐of‐the‐Art, Current Prospects, and Future Challenges
Zarrintaj, P., Saeb, M. R., Stadler, F. J., Yazdi, M. K., Nasirinezhad, M., Mohebbi, S., Seidi, F., Saeb, M. R., & Mozafari, M. (2021) · Advanced Biology · doi:10.1002/adbi.202000526 · Cited by 49
Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse
Song, T., Qin, W., Lai, Z., Li, H., Li, D., Wang, B., Deng, W., Wang, T., Wang, L., & Huang, R. (2023) · Cell Research · doi:10.1038/s41422-023-00800-8 · Cited by 49
Wharton, S., le Roux, C. W., Kosiborod, M., Platz, E., Brueckmann, M., Jastreboff, A. M., Hussain, S. A., Pedersen, S. D., Borowska, L., Unseld, A., et al. (2024) · Obesity · doi:10.1002/oby.24184 · Cited by 40
Chaisiwamongkhol, K., Labaidae, S., Pon-in, S., Pinsrithong, S., Bunchuay, T., & Phonchai, A. (2020) · Microchemical Journal · doi:10.1016/j.microc.2020.105273 · Cited by 39
Claridy, M. D., Czepiel, K. S., Bajaj, S. S., & Stanford, F. C. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.07.021 · Cited by 37
DDIGIP: predicting drug-drug interactions based on Gaussian interaction profile kernels
Yan, C., Duan, G., Pan, Y. F., Wu, F., & Wang, J. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3093-x · Cited by 37
Song, M. S., Lim, S.-K., Wang, J., & Kim, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010278 · Cited by 37
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Sandsdal, R. M., Juhl, C. R., & Torekov, S. S. (2019) · Drug Safety · doi:10.1007/s40264-019-00812-7 · Cited by 37
Garvey, W. T., Mahle, C. D., Bell, T., & Kushner, R. F. (2024) · Obesity Science & Practice · doi:10.1002/osp4.756 · Cited by 40
Yang, S., Huang, W.-C., Ng, X. E., Lee, M., Hsu, Y.-J., Huang, C., Wu, H.-H., Yeh, C., Shirakawa, H., Budijanto, S., et al. (2019) · Nutrients · doi:10.3390/nu11092033 · Cited by 34
Chen, X., Liu, Y., Guo, Z., Chen, Y., Li, M., Huang, C., Chen, Z., & Meng, X. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5232 · Cited by 33
Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
Tian, H., Zhang, S., Liu, Y., Wu, Y., & Zhang, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054583 · Cited by 33
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview
Çaklılı, Ö. T., Cesur, M., Mikhailidis, D. P., & Rizzo, M. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s392684 · Cited by 35
Tung, Y., Zeng, J., Ho, S., Xu, J.-W., Li, S., & Wu, J. (2021) · Antioxidants · doi:10.3390/antiox10111694 · Cited by 31
Manzoor, M., Muroi, M., Ogawa, N., Kobayashi, H., Nishimura, H., Chen, D., Fasina, O. B., Wang, J., Osada, H., Yoshida, M., et al. (2022) · Food & Function · doi:10.1039/d2fo02438a · Cited by 31
Gryshkova, V., Fleming, A., McGhan, P., Ron, P. D., Fleurance, R., Valentin, J., & da Costa, A. N. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.01.013 · Cited by 29
Spray Dried Smectite Clay Particles as a Novel Treatment against Obesity
Dening, T. J., Joyce, P., Kovalainen, M., Gustafsson, H., & Prestidge, C. A. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2552-9 · Cited by 29
Comoglio, R. H. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14179 · Cited by 28
Safety Surveillance During Drug Development: Comparative Evaluation of Existing Regulations
Samara, C., Garcia, A., Henry, C., Vallotton, L., Cariolato, L., Desmeules, J. A., & Pinçon, A. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02492-3 · Cited by 27
Iannone, A., Natale, P., Palmer, S. C., Nicolucci, A., Rendina, M., Giorgino, F., Laviola, L., Di Leo, A., & Strippoli, G. F. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15138 · Cited by 27
İlaca Bağlı Kardiyovasküler Risk: Geri Çekilen İlaçların Retrospektif Değerlendirilmesi
Kocadal, K. (2018) · Northern Clinics of Istanbul · doi:10.14744/nci.2018.44977 · Cited by 26
Semaglutide for weight loss: unanswered questions
Tzoulis, P., & Baldeweg, S. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1382814 · Cited by 26
Saeed, M., Ghadiri, A., Hadizadeh, F., Attaranzadeh, A., Alavi, M. S., & Etemad, L. (2018) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2018.35368.8427 · Cited by 25
Radwan, R. M., Lee, Y. A., Kotecha, P., Wright, D. R., Hernandez, I., Ramon, R., Donahoo, W. T., Chen, Y., Allen, J. M., Bian, J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16318 · Cited by 24
Evolving Approaches for Pharmacological Therapy of Obesity
Chao, A. M., Taylor, S. I., Moore, M., Amaro, A., & Wadden, T. A. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031124-101146 · Cited by 29
Lopes, B. T., Caldeira, M. J., Gaspar, H., & Antunes, A. M. M. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2020.609251 · Cited by 24
The risk of cardiovascular complications with current obesity drugs
Chao, A. M., Wadden, T. A., Berkowitz, R. I., Quigley, K., & Silvestry, F. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1806234 · Cited by 23
Liver Acinus Dynamic Chip for Assessment of Drug-Induced Zonal Hepatotoxicity
Kwon, D., Choi, G., Park, S.-A., Cho, S., Cho, S., & Ko, S. (2022) · Biosensors · doi:10.3390/bios12070445 · Cited by 24
Kalyanasundar, B., Pérez-Díaz, C. I., Arroyo, B., Moreno, M. G., & Gutiérrez, R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.572328 · Cited by 22
Eraniappan, S., Balasubramaniyan, P., Uddandrao, V. V. S., Roy, A., & Sengottuvelu, S. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12871 · Cited by 22
Hispidulin inhibits adipogenesis in 3T3-L1 adipocytes through PPARγ pathway
Lee, S. G., Kim, J. S., Min, K., Kwon, T. K., & Nam, J. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.07.027 · Cited by 22
Brown, J. P., Wing, K., Evans, S. J. W., Bhaskaran, K., Smeeth, L. L., & Douglas, I. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028133 · Cited by 21
Nanogel-based nasal vaccines for infectious and lifestyle-related diseases
Azegami, T., Yuki, Y., Nakahashi-Ouchida, R., Itoh, H., & Kiyono, H. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.10.022 · Cited by 22
Semaglutide: a new drug for the treatment of obesity
Lexchin, J., & Mintzes, B. J. (2023) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2023.000007 · Cited by 20
Lesser Investigated Natural Ingredients for the Management of Obesity
Majeed, M. A., Majeed, S., Nagabhushanam, K., Muthuraman, G., & Mundkur, L. (2021) · Nutrients · doi:10.3390/nu13020510 · Cited by 20
Butucă, A., Dobrea, C. M., Arseniu, A. M., Frum, A., Chiş, A. A., Rus, L. L., Ghibu, S., Juncan, A. M., Muntean, A. C., Lazăr, A. E., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12051124 · Cited by 24
Gorelik, E., Gorelik, B., Masarwa, R., Perlman, A., Raccah, B. H., & Matok, I. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0544-4 · Cited by 19
Pharmacological Treatments and Natural Biocompounds in Weight Management
Gasmi, A., Mujawdiya, P. K., Nehaoua, A., Shanaida, M., Semenova, Y. M., Piscopo, S., Menzel, A., Voloshyn, V., Voloshyn, O., Shanaida, V., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020212 · Cited by 21
Anti-Adipogenic Effect of Neferine in 3T3-L1 Cells and Primary White Adipocytes
Park, M., Han, J.-Y., & Lee, H. (2020) · Nutrients · doi:10.3390/nu12061858 · Cited by 19
Rao, M. S., Nassiri, V., Srivastava, S., Yang, A. H., Brar, S., McDuffie, E., & Sachs, C. W. (2024) · Pharmaceuticals · doi:10.3390/ph17111550 · Cited by 19
Kang, N., Oh, S., Kim, S.-Y., Ahn, H., Son, M., Heo, S., Byun, K., & Jeon, Y. (2021) · Algal Research · doi:10.1016/j.algal.2021.102533 · Cited by 18
Overcoming obesity: Weight-loss drugs are underused
Kanj, A., & Levine, D. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.19102 · Cited by 17
Rubino, F., Logue, J., Bøgelund, M., Madsen, M. E., Cancino, A., Høy, M., & Panton, U. H. (2021) · Obesity Science & Practice · doi:10.1002/osp4.518 · Cited by 19
Kim, K. K. (2019) · Korean Journal of Family Medicine · doi:10.4082/kjfm.19.0013 · Cited by 18
Availability and composition of weight‐loss supplements in Sri Lanka
Jayawardena, R., Sooriyaarachchi, P., Ranasinghe, P. D., Perera, A., & Hills, A. P. (2018) · Nutrition & Dietetics · doi:10.1111/1747-0080.12501 · Cited by 18
Sharma, M. K., Machhi, J., Murumkar, P. R., & Yadav, M. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-20078-w · Cited by 16
Glenny, E. M., Coleman, M. F., Clutton, G. T., Riesenberg, B. P., Ho, A. N., McFarlane, T. L., Kiesel, V. A., Kucinskas, A. L., Bailey, E. G., Sanchez, K. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.20.576484 · Cited by 17
Pharmacologic Weight Management in the Era of Adolescent Obesity
Raman, V. S., Gupta, A., Ashraf, A. P., Breidbart, E., Gourgari, E., Kamboj, M. K., Kohn, B., Krishnan, S., Lahoti, A., Matlock, K. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac418 · Cited by 15
Choi, Y. J., Choi, C.-Y., Kim, C. U., & Shin, S. (2023) · Journal of Global Health · doi:10.7189/jogh.13.04095 · Cited by 15
DARK Classics in Chemical Neuroscience: Aminorex Analogues
Maier, J., Mayer, F. P., Brandt, S. D., & Sitte, H. H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00415 · Cited by 15
Spithoff, S. M., Vesely, L., McPhail, B. M., Rowe, R., Mogic, L., & Grundy, Q. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.7688 · Cited by 12
Luo, S., Lenon, G. B., Gill, H. S., Yuen, H., Yang, A. W. H., Hung, A., & Nguyen, L. T. (2018) · Current Drug Targets · doi:10.2174/1389450119666180830125958 · Cited by 14
A Historical Overview Upon the Use of Amphetamine Derivatives in the Treatment of Obesity
Stăcescu, Ș., Hancu, G., Podar, D., Todea, Ș., & Tero-Vescan, A. (2020) · Journal of Pharmaceutical Care · doi:10.18502/jpc.v7i3.2355 · Cited by 14
Obesity and climate change: co-crises with common solutions
Behrens, P., Champagne, C. M., Halford, J. C. G., Moodie, M., Proietto, J., Rutter, G. A., Samaras, K., & Holly, J. M. P. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1613595 · Cited by 13
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
d’Ávila, M., Hall, S., & Horváth, T. L. (2024) · Endocrinology · doi:10.1210/endocr/bqae128 · Cited by 13
Yeung, A. W. K., Hammerle, F. P., Behrens, S., Matin, M., Mickael, M., Litvinova, O., Parvanov, E. D., Kletečka-Pulker, M., & Atanasov, A. G. (2025) · JMIR Infodemiology · doi:10.2196/59767 · Cited by 13
Playdon, M. C., Hardikar, S. S., Karra, P., Hoobler, R., Ibele, A. R., Cook, K. L., Kumar, A., Ippolito, J. E., & Brown, J. C. (2023) · JNCI Monographs · doi:10.1093/jncimonographs/lgad003 · Cited by 12
Pharmacological therapies to address obesity in type 1 diabetes
Casu, A., Bilal, A., & Pratley, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000555 · Cited by 13
Pinckaers, N. E. T., Blankesteijn, W. M., Mircheva, A., Shi, X., Opperhuizen, A., van Schooten, F., & Vrolijk, M. F. (2024) · Nutrients · doi:10.3390/nu16111567 · Cited by 11
Nie, Y., Littleton, B., Kavanagh, T., Abbate, V., Bansal, S. S., Richards, D. R., Hylands, P. J., & Stürzenbaum, S. R. (2017) · The FASEB Journal · doi:10.1096/fj.201700438r · Cited by 11
Herbal supplements interactions with oral oestrogen‐based contraceptive metabolism and transport
Hlengwa, N., Muller, C. J. F., Basson, A. K., Bowles, S., Louw, J., & Awortwe, C. (2020) · Phytotherapy Research · doi:10.1002/ptr.6623 · Cited by 13
Khattab, A., Ahmed-Farid, O. A.-H., & Nasr, S. A. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102276 · Cited by 11
Kim, I., Choi, J., Lee, M., Kwon, C., & Nam, T. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3295 · Cited by 11
Ngo, L. T., Yang, S., Shin, S., Cao, D. T., Nguyen, H. V., Jung, S., Lee, J., Lee, J., Yun, H., & Chae, J. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12844 · Cited by 10
Sarayani, A., Hampp, C., Brown, J. D., Donahoo, W. T., & Winterstein, A. G. (2022) · Drug Safety · doi:10.1007/s40264-022-01244-6 · Cited by 10
Su, Y., Choi, H.-S., Choi, J.-H., Kim, H.-S., Lee, G.-Y., Cho, H.-W., Choi, H., Jang, Y., & Seo, J. (2023) · Nutrients · doi:10.3390/nu15020427 · Cited by 10
Chang, Y. B., Ahn, Y., Seo, D.-B., Bae, S., Suh, H. J., Hong, Y. H., & Jung, E. Y. (2023) · Applied Biological Chemistry · doi:10.1186/s13765-023-00846-7 · Cited by 10
Maejima, Y., Yokota, S., Hidema, S., Nishimori, K., de Wet, H., & Shimomura, K. (2024) · Neuroendocrinology · doi:10.1159/000538792 · Cited by 12
Mirghani, S. J., Peeri, M., Yekani, O. Y., Zamani, M., Feizolahi, F., Nikbin, S., Derakhshideh, A., Mousavi, N., Khojasteh, Z., Nasrollahi, Z., et al. (2018) · JMIR Research Protocols · doi:10.2196/10753 · Cited by 10
Impact of A Cargo-Less Liposomal Formulation on Dietary Obesity-Related Metabolic Disorders in Mice
Komalla, V., Sheikholeslami, B., Li, G., Bokshi, B., Chan, Y. L., Ung, A. T., Oliver, B. G. G., Chen, H., & Haghi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207640 · Cited by 9
Vardanyan, G., Harutyunyan, H. S., Aghajanov, M. I., & Vardanyan, R. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0361 · Cited by 9
Many Cells Make Life Work—Multicellularity in Stem Cell-Based Cardiac Disease Modelling
Wang, B., Kit‐Anan, W., & Terracciano, C. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113361 · Cited by 13
Song, J., Kim, D.-Y., Lee, H., Rhee, S. Y., & Lim, H. (2024) · Nutrients · doi:10.3390/nu16040494 · Cited by 9
Lorcaserin in obesity: minimal benefits and ill-defined harms
Onakpoya, I., & Aronson, J. K. (2019) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2018-111128 · Cited by 9
Self-citationReducing Effect of Farnesylquinone on Lipid Mass in C. elegans by Modulating Lipid Metabolism
Jia, X., Xu, M., Yang, A., Zhao, Y., Liu, D., Huang, J., Proksch, P., & Lin, W. (2019) · Marine Drugs · doi:10.3390/md17060336 · Cited by 8
A review on drug repurposing applicable to obesity
Chen, F., Jing, K., Zhang, Z., & Liu, X. (2024) · Obesity Reviews · doi:10.1111/obr.13848 · Cited by 7
A review: Anti-obesity drug discovery from natural plant metabolites and endogenous peptides
Zhu, X., Wang, D., & Atanasov, A. G. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100259 · Cited by 8
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 11
Bhalerao, S. S., Joshi, A. A., Khadke, S. P., & Sathiyanarayan, A. (2023) · Pharmacognosy Magazine · doi:10.1177/09731296231198316 · Cited by 7
Chinchu, J. U., Mohan, M. C., & Kumar, B. P. (2019) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2019.100309 · Cited by 7
Elarabany, N., Hamad, A., & Al-Sobeai, S. M. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14265 · Cited by 7
Metadata
- Authors
- Onakpoya, I. J., Heneghan, C. J., & Aronson, J. K.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Onakpoya, Igho J.
- Venue
- BMC Medicine
- Published
- 2016-11-29
- Volume
- 14
- Issue
- 1
- Pages
- 191-191
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC5126837
- OpenAlex
- W2551793627
- Cited by
- 171
- References
- 52
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 26 · 2023: 24 · 2022: 13 · 2021: 20 · 2020: 17 · 2019: 15 · 2018: 24 · 2017: 7 · 2016: 1
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- British Pharmacological Society
- University of Oxford
- U.S. Food and Drug Administration
- NIHR School for Primary Care Research
- Clarendon Fund
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- anti-obesity drugs, drug withdrawal, adverse drug reactions, monoamines, psychiatric disturbances, cardiotoxicity, drug addiction, drug abuse, level of evidence, regulatory decision-making, obesity treatment
- MeSH terms
- Humans, Obesity, Product Surveillance, Postmarketing, Safety-Based Drug Withdrawals, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
